NCCN Research & Business Resources
NCCN and Pfizer, Inc. Grant Opportunity
National Comprehensive Cancer Network® (NCCN®) is pleased to announce that it is collaborating with Pfizer’s Independent Grants for Learning & Change (IGLC) team to offer a grant opportunity focused on improving care for patients with rare types of cancers such as renal cell carcinoma and certain hematologic malignancies, where treatment options are complex and rapidly advancing. The Request for Proposals (RFP) clearly outlines the scope and process that will be followed for the submission of Letters of Intent (LOIs).
The intent of this RFP is to encourage organizations to submit LOIs describing concepts and ideas for design and implementation of systems or programs that close clinical practice gaps and improve the care of patients with rare cancer types through the establishment of education and support mechanisms for community oncologists.
NCCN views this collaboration with Pfizer’s IGLC team as clear recognition of the advantages offered to industry through the NCCN Oncology Research Program. We hope you and your colleagues will be interested in this opportunity.
LOIs are due by 11:59 PM EST, Thursday, December 5, 2013. If you have any questions regarding this RFP, please direct them in writing to the Grant Officer for this clinical area, Jacqueline Waldrop at Jacqueline.email@example.com with the subject line, “Oncology Communities RFP.”